Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:28 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 1,736 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo Administration first Clear all

Conditions: HIV-1-infection, Methamphetamine-dependence
Interventions: Oral Methamphetamine, Placebo oral capsule; Drug · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 65 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Breast Pain, Non-cyclical Mastalgia, Surgical Scar-Related Breast Pain
Interventions: Diclofenac, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Anxiety Disorder
Interventions: Continued Paroxetine CR, Quetiapine, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 72 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 2
States / cities: Boston, Massachusetts • Durham, North Carolina

Conditions: Cervical Dystonia
Interventions: transcranial direct current stimulation; Device
Lead sponsor: University of Minnesota; Other
Eligibility: 21 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Glioma
Interventions: rhIL-7-hyFc, Placebo, Temozolomide, Radiation therapy; Drug · Radiation
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Healthy Subjects
Interventions: PF-06882961, Placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Tiotropium/Salmeterol, Salmeterol, Placebo, Tiotropium; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 207 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 16
States / cities: Anniston, Alabama • Mobile, Alabama • Clearwater, Florida + 10 more

Conditions: Nicotine Dependence
Interventions: Belsomra, Placebo, Methylphenidate; Drug
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 140 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Asthma
Interventions: Imatinib mesylate, Placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 7
States / cities: Birmingham, Alabama • Boston, Massachusetts • St Louis, Missouri + 4 more

Conditions: Systemic Lupus Erythematosus
Interventions: Belimumab 10 mg/kg, Placebo; Drug · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2025
U.S. locations: 7
States / cities: Phoenix, Arizona • Washington D.C., District of Columbia • Augusta, Georgia + 4 more

Conditions: Attention Deficit Hyperactivity Disorder (ADHD), Executive Function Deficits (EFD)
Interventions: Placebo, Memantine Hydrochloride, OROS-Methylphenidate; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 50 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Type 2 Diabetes Mellitus
Interventions: Dapagliflozin, Metformin XR, dapagliflozin matching Placebo, metformin HCl Modified Release matching Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 77 Years
Enrollment: 1,093 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 64
States / cities: Ozark, Alabama • Tempe, Arizona • Concord, California + 53 more

Conditions: HIV-associated Co-morbidities
Interventions: conventional vitamin D treatment, tiered/titrated vitamin D dosing; Dietary Supplement · Drug
Lead sponsor: Andrea Branch; Other
Eligibility: 18 Years to 70 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Complex Regional Pain Syndrome, Chronic Pain, Causalgia, Complex Regional Pain Syndrome Type I, Complex Regional Pain Syndrome Type II
Interventions: Low dose naltrexone, Placebo sugar capsules; Drug
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 18 Years to 85 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Alcohol Use Disorder (AUD), PTSD
Interventions: Psilocybin 25 mg, Maltodextrin (Placebo); Drug
Lead sponsor: Nathan Brashares Sackett; Other
Eligibility: 21 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Polycystic Ovary Syndrome
Interventions: Metformin, Oral Contraceptive Pill, Lifestyle Management Program, Quality of Life Questionnaire, Oral Glucose Tolerance Test, Blood work, Abdominal Ultra Sound, Dual-energy x-ray absorptiometry (DEXA scan), placebo; Drug · Behavioral · Procedure
Lead sponsor: University of Rochester; Other
Eligibility: 12 Years to 18 Years · Female only
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Type 1 Diabetes (T1D)
Interventions: Cadisegliatin 800 mg QD, Placebo; Drug
Lead sponsor: vTv Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 6
States / cities: Modesto, California • San Diego, California • Aurora, Colorado + 3 more

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: Telmisartan, Placebo, Clozapine, Olanzapine; Drug
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 18 Years to 65 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Asthma
Interventions: FP, SFC, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Systemic Allergic Reaction
Interventions: Pfizer-BioNTech COVID-19 Vaccine (Comirnaty), Placebo, Pfizer-BioNTech COVID-19 Vaccine, Bivalent; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 16 Years to 69 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Pneumonia, Idiopathic Pneumonia Syndrome
Interventions: Etanercept, Placebo plus corticosteroid; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 12
States / cities: Gainesville, Florida • Indianapolis, Indiana • Baltimore, Maryland + 9 more

Conditions: Arterial Disease of Legs, Below-the-knee Obstruction, PAD - Peripheral Arterial Disease
Interventions: MagicTouch PTA Sirolimus drug coated balloon, Placebo balloon angioplasty; Device
Lead sponsor: Concept Medical Inc.; Industry
Eligibility: 21 Years and older
Enrollment: 368 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 29
States / cities: Scottsdale, Arizona • Los Angeles, California • Clearwater, Florida + 22 more

Conditions: Warm Antibody Autoimmune Hemolytic Anemia
Interventions: Fostamatinib disodium, Placebo; Drug
Lead sponsor: Rigel Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 26
States / cities: Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 22 more

Conditions: Myeloma
Interventions: Placebo, Minocycline; Other · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

Effect of Methamphetamine on Residual Latent HIV Disease Study

Treatment of Breast Pain Using A Medication (Diclofenac) Applied to the Skin

Combination of Paroxetine CR and Quetiapine for the Treatment of Refractory Generalized Anxiety Disorder

tDCS in Cervical Dystonia

rhIL-7-hyFc on Increasing Lymphocyte Counts in Patients With Newly Diagnosed Non-severe Lymphopenic Gliomas Following Radiation and Temozolomide

First In Human, Single Escalating Oral Dose Study Of PF-06882961 In Healthy Adult Subjects

Tiotropium/Salmeterol Inhalation Powder in COPD

Orexin s Role in the Neurobiology of Substance Use Disorder

Effects of cKit Inhibition by Imatinib in Patients With Severe Refractory Asthma (KIA)

Pediatric Lupus Trial of Belimumab Plus Background Standard Therapy

Memantine for Executive Dysfunction in Adults With ADHD: A Pilot Study

Study of Dapagliflozin in Combination With Metformin XR to Initiate the Treatment of Type 2 Diabetes

Vitamin D Supplements for HIV-positive Patients on cART

Low Dose Naltrexone Therapy for Complex Regional Pain Syndrome

PsiloStudy: Psilocybin With Psychological Support (Psi-PS) for Military Veterans and First Responders With Co-occurring PTSD & Alcohol Use Disorder (AUD)

Impact of Metformin in Teens With Polycystic Ovary Syndrome (PCOS) on Oral Contraceptive Therapy

Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes Who Are Using Hybrid Closed Loop (HCL) Systems

Telmisartan as an Adjunctive Treatment for Metabolic Problems in Patients With Schizophrenia

Study Of Fluticasone Propionate/Salmeterol In Asthmatic Subjects

The Safety of Administering a Second Dose of a COVID-19 mRNA Vaccine in Individuals Who Experienced a Systemic Allergic Reaction to an Initial Dose

Effectiveness of Etanercept for Idiopathic Pneumonia Syndrome Following Stem Cell Transplantation (BMT CTN 0403)

Sirolimus Coated BALloon Versus Standard Balloon Angioplasty in The Treatment of Below The Knee Arterial Disease

A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHA

Prevention of Treatment Induced Neuropathy in Multiple Myeloma